[{"id":"db660b09-0f52-4a82-9f38-79007e8d5211","acronym":"MORPHEUS mUC","url":"https://clinicaltrials.gov/study/NCT03869190","created_at":"2021-01-18T19:04:50.965Z","updated_at":"2025-02-25T13:18:52.965Z","phase":"Phase 1/2","brief_title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","source_id_and_acronym":"NCT03869190 - MORPHEUS mUC","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • gemcitabine • Zejula (niraparib) • Trodelvy (sacituzumab govitecan-hziy) • Padcev (enfortumab vedotin-ejfv) • magrolimab (ONO-7913) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • RG7827 • lomvastomig (RG7769)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 10/03/2024","primary_completion_date":" 10/03/2024","study_txt":" Completion: 05/21/2026","study_completion_date":" 05/21/2026","last_update_posted":"2025-01-03"}]